Collaborative Effort Begins Between OpenAI and Retro Biosciences to Advance Longevity Studies
In an exciting development, OpenAI and Retro Biosciences are partnering to explore the potential of artificial intelligence (AI) in biological research. The collaboration, supported by OpenAI CEO Sam Altman, aims to extend human lifespans by 10 years and improve health in old age, going beyond mere lifespan extension.
The focus of this partnership is the modification of Yamanaka factors, proteins capable of transforming old skin cells into young stem cells. This groundbreaking research could revolutionise regenerative medicine and potentially reverse cellular aging.
OpenAI has developed a large language model called GPT-4b micro for medical and scientific endeavours. While the specific role of GPT-4b micro in this collaboration is not yet clear, it's known that researchers have utilised suggestions generated by the model to enhance two Yamanaka factors, making them "over 50 times more effective."
Retro Biosciences believes these enhanced proteins could be critical for tissue regeneration, artificial organ development, and life extension. The potential benefits of this research extend far beyond lifespan extension, offering promising prospects for healthcare in the future.
Preliminary assessments indicate that the enhanced proteins significantly outperform what scientists could achieve on their own. John Hollman, an OpenAI researcher, stated that this research could be a significant advancement in medicine.
However, it's important to note that while the collaboration between Retro Biosciences and OpenAI is underway, specific details about recent developments related to extending human lifespans through Yamanaka factors and the GPT-4B model are not yet available.
As this research progresses, we can expect to see further updates on the exciting developments in the field of AI-based biological research and its potential impact on human health and lifespan.
The partnership between OpenAI and Retro Biosciences, focusing on AI-enhanced biological research, extends beyond mere lifespan extension, venturing into health and wellness advancements. This collaboration, spearheaded by OpenAI CEO Sam Altman, aims to modify Yamanaka factors with the help of technology and general news about the development of GPT-4b micro, a language model designed for medical and scientific endeavors, could play a significant role.
